Wells Fargo analyst Derek Archila lowered the firm’s price target on Cabaletta Bio (CABA) to $2 from $3 and keeps an Equal Weight rating on the shares. The firm thinks the company’s recent financing gives it time to gain more regulatory clarity for rese-cel in MG, SSc and SLE, but still falls short of its first BLA submission expected in 2027. Sentiment remains challenging and Wells expects shares to be range bound.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CABA:
- Cabaletta Bio Reports Progress in Clinical Trials
- Cabaletta Bio: Strong Financial Position and Strategic Clinical Advancements Drive Buy Rating
- Cabaletta Bio’s Promising Clinical Study on CABA-201 for Myasthenia Gravis
- Cabaletta Bio files $240M mixed securities shelf
- Cabaletta Bio reports Q2 EPS (73c), consensus (61c)